Tisch Cancer Institute


Mount Sinai Researchers Discover How Early-Stage Breast Cancer Can Become a Silent Killer in Some Patients

July 19th 2022

Mount Sinai researchers have discovered a previously unknown mechanism in which not-yet-malignant cells from early breast cancer tumors travel to other organs and, eventually, “turn on” and become metastatic breast cancer.

Biomarker in Liquid Biopsy for Lung Cancer Appears More Accurate in Predicting Immunotherapy Response Than Tumor Biopsy

July 1st 2022

Study findings could be developed into less-invasive method.

Mount Sinai Receives Grant to Enhance Patient-Centric, Team-Based Pancreatic Cancer Care

May 31st 2022

The Canopy Cancer Collective, a national nonprofit organization that strives to fuel better treatments and outcomes for pancreatic cancer patients, has awarded The Tisch Cancer Institute at Mount Sinai a $500,000 grant to support continued innovation in its multidisciplinary treatment of pancreatic cancer.

Mount Sinai’s Natasha Kyprianou, MBBS, PhD, to Receive American Urological Association’s Richard D. Williams, MD, Prostate Cancer Research Excellence Award

May 26th 2022

Mount Sinai researcher Natasha Kyprianou, MBBS, PhD, a leading expert on prostate, bladder, and kidney cancer, has been awarded the Richard D. Williams, MD, Prostate Cancer Research Excellence Award by the Urology Care Foundation, the world’s leading nonprofit urological health foundation and official foundation of the American Urological Association.

Scientists Discover Gene Mutation That Signals Aggressive Melanoma

May 18th 2022

Mutation of a gene called ARID2 plays a role in increasing the chance that melanoma, a deadly skin cancer, will turn dangerously metastatic.

Mount Sinai Researchers Develop Novel Method to Identify and Treat Aggressive Early-Stage Lung Cancers

May 9th 2022

Mount Sinai researchers have developed a novel method to identify aggressive early-stage lung cancers and target drugs known as aurora kinase inhibitors to tumors that are especially likely to respond to them.

Third Dose of COVID-19 Vaccine Significantly Increases Immune Responses in Most Patients With Multiple Myeloma

May 4th 2022

Most immunocompromised people with multiple myeloma benefited from a third dose of COVID-19 vaccines. However, some people with multiple myeloma still remained vulnerable and may need a fourth dose or antibody treatments as restrictions lift and new variants emerge

Molecular Treatment Is Able to Control Brain Metastasis of Different Tumors

May 3rd 2022

Mount Sinai researchers conducting clinical trials of a drug targeting a cancer gene found that it increased metastatic cancer patients’ survival and was able to work within the brain.

Mount Sinai Researchers Report Increasing Incidence of Early-Onset Colorectal Precancerous Lesions in First-of-Its-Kind Study of Patients Under Age 50

April 7th 2022

Researchers at the Icahn School of Medicine at Mount Sinai describe a troubling increase in early-onset colorectal cancer and precancerous polyps, based on a large, nationally representative study of patients under age 50 who underwent colonoscopy.

Immunotherapy Before Liver Cancer Surgery Can Kill Tumor, and Likely Residual Cancer Cells

April 3rd 2022

Results from first-of-its-kind Mount Sinai study show that immunotherapy before liver cancer surgery can kill tumor, and likely residual cancer cells.

Novel CRISPR Imaging Technology Reveals Genes Controlling Tumor Immunity

March 30th 2022

Next-generation spatial genomics technology paves the way for accelerating the discovery of new cancer drug targets

Mount Sinai and Samuel Waxman Cancer Research Foundation to Collaborate Against the Rising Incidence of Cancer Due to Aging

February 9th 2022

The Tisch Cancer Institute at Mount Sinai and the Samuel Waxman Cancer Research Foundation are launching a unique research program that will fund collaborations between TCI physician-scientists and colleagues from other established cancer research institutions to address the rising rates of cancer due to aging around the world.